Stocks · News reference
Aurora Cannabis urges shareholders to reject Curaleaf's unsolicited hostile bid, calling the offer undervaluation with serious risks.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Curaleaf's hostile and opportunistic bid significantly undervalues Aurora, and aims to capture Aurora's assets at a discountAurora is debt free and holds $149 million in cash1, Curaleaf carries over $1 billion
https://x.com/DougKass/status/2093394146182480247
Curaleaf has launched a hostile takeover bid for Aurora Cannabis at $4 per share, which Aurora's board has rejected. While Aurora has transformed into a leaner, profitable medical cannabis company with strong international operations and a solid balance sheet, investors shouldn't buy the stock purely as a takeover bet. The company's genuine turnaround in medical cannabis and European expansion could make Curaleaf's offer undervalued, but there's no guarantee the deal will close or be increased.
Filed: 2026-09-02 AccNo: 0001756770-26-000090 Size: 2 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Curaleaf proposes to acquire Aurora Cannabis for $4 per share, offering a 45% premium to expand global operations.